

CITATION REPORT

List of articles citing

Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study

DOI: 10.1093/eurjhf/hfr147

European Journal of Heart Failure, 2012, 14, 82-90.

Source: <https://exaly.com/paper-pdf/52561514/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
95	Pulmonary hypertension due to left heart disease. <i>Circulation</i> , 2012 , 126, 975-90	16.7	294
94	Sildenafil improves microvascular O2 delivery-to-utilization matching and accelerates exercise O2 uptake kinetics in chronic heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012 , 303, H1474-80	5.2	42
93	Pulmonary hypertension associated with left-sided heart disease. <i>Heart Failure Clinics</i> , 2012 , 8, 447-59	3.3	24
92	Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials. <i>Current Heart Failure Reports</i> , 2012 , 9, 192-9	2.8	26
91	Assessing the impact of heart failure therapeutics on quality of life and functional capacity. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013 , 15, 425-36	2.1	10
90	Management of pulmonary hypertension in left heart disease. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2013 , 7, 131-51	3.4	9
89	Left ventricular dysfunction with pulmonary hypertension: part 2: prognosis, noninvasive evaluation, treatment, and future research. <i>Circulation: Heart Failure</i> , 2013 , 6, 584-93	7.6	22
88	Adaptive servo-ventilation improves exercise oscillatory ventilation and ventilatory inefficiency in patients with heart failure and central sleep apnea. <i>IJC Metabolic & Endocrine</i> , 2013 , 1, 20-26		4
87	Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 1268-77	27.4	762
86	Inspiratory muscle training in heart disease and heart failure: a review of the literature with a focus on method of training and outcomes. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 161-77	2.5	59
85	The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. <i>Journal of the American Heart Association</i> , 2013 , 2, e000536	6	82
84	Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design. <i>European Journal of Heart Failure</i> , 2013 , 15, 119-22	12.3	35
83	Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. <i>BMC Medicine</i> , 2014 , 12, 185	11.4	58
82	Echocardiographic assessment of pulmonary artery systolic pressure and outcomes in ambulatory heart failure patients. <i>Journal of the American Heart Association</i> , 2014 , 3, e000363	6	26
81	Riociguat for pulmonary hypertension. <i>Expert Review of Clinical Pharmacology</i> , 2014 , 7, 259-70	3.8	6
80	Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis. <i>European Journal of Heart Failure</i> , 2014 , 16, 444-53	12.3	19
79	Revisiting cardiopulmonary exercise testing applications in heart failure: aligning evidence with clinical practice. <i>Exercise and Sport Sciences Reviews</i> , 2014 , 42, 153-60	6.7	21

78	Abnormalities in cardiopulmonary exercise testing ventilatory parameters in heart failure: pathophysiology and clinical usefulness. <i>Current Heart Failure Reports</i> , 2014 , 11, 80-7	2.8	20
77	Pathophysiology and potential treatments of pulmonary hypertension due to systolic left heart failure. <i>Acta Physiologica</i> , 2014 , 211, 314-33	5.6	12
76	Prevention of right heart failure after left ventricular assist device implantation by phosphodiesterase 5 inhibitor. <i>Artificial Organs</i> , 2014 , 38, 963-7	2.6	34
75	PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2014 , 172, 581-7	3.2	30
74	Prognostic respiratory parameters in heart failure patients with and without exercise oscillatory ventilation - a systematic review and descriptive meta-analysis. <i>International Journal of Cardiology</i> , 2015 , 182, 476-86	3.2	33
73	Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS. <i>British Journal of Pharmacology</i> , 2015 , 172, 1397-414	8.6	21
72	Altered breathing syndrome in heart failure: newer insights and treatment options. <i>Current Heart Failure Reports</i> , 2015 , 12, 158-65	2.8	10
71	Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with HFrEF. <i>Hypertension Research</i> , 2015 , 38, 829-39	4.7	11
70	Inflammation in HFpEF: Key or circumstantial?. <i>International Journal of Cardiology</i> , 2015 , 189, 259-63	3.2	31
69	An overview of the applied definitions and diagnostic methods to assess exercise oscillatory ventilation--a systematic review. <i>International Journal of Cardiology</i> , 2015 , 190, 161-9	3.2	29
68	Pathophysiology and clinical relevance of pulmonary remodelling in pulmonary hypertension due to left heart diseases. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 416-29	3.8	25
67	Cardiopulmonary Exercise Testing in Heart Failure. <i>Current Problems in Cardiology</i> , 2015 , 40, 322-72	17.1	46
66	Erectile dysfunction and its management in patients with diabetes mellitus. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2015 , 16, 213	10.5	19
65	Group 2 PH: Medical Therapy. <i>Progress in Cardiovascular Diseases</i> , 2016 , 59, 71-7	8.5	3
64	Physiological Techniques and Pulmonary Hypertension - Left Heart Disease. <i>Progress in Cardiovascular Diseases</i> , 2016 , 59, 30-41	8.5	1
63	Physiological and sensory consequences of exercise oscillatory ventilation in heart failure-COPD. <i>International Journal of Cardiology</i> , 2016 , 224, 447-453	3.2	15
62	Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016 , 41, 119-27	2.2	10
61	Pulmonary hypertension in patients with heart failure and preserved ejection fraction: differential diagnosis and management. <i>Pulmonary Circulation</i> , 2016 , 6, 3-14	2.7	15

60	Sildenafil in heart failure with reactive pulmonary hypertension (Sildenafil HF) clinical trial (rationale and design). <i>Pulmonary Circulation</i> , 2016 , 6, 161-7	2.7	6
59	Pulmonary artery wedge pressure and exercise oscillatory ventilation in pre-capillary pulmonary hypertension. <i>International Journal of Cardiology</i> , 2016 , 206, 164-6	3.2	3
58	Sildenafil ameliorates left ventricular T-tubule remodeling in a pressure overload-induced murine heart failure model. <i>Acta Pharmacologica Sinica</i> , 2016 , 37, 473-82	8	14
57	Response to the letter "Pulmonary artery wedge pressure and exercise oscillatory ventilation in pre-capillary pulmonary hypertension". <i>International Journal of Cardiology</i> , 2016 , 204, 12	3.2	
56	From comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress. <i>Heart</i> , 2016 , 102, 320-30	5.1	17
55	Exercise oscillatory ventilation in heart failure and in pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2016 , 202, 736-40	3.2	24
54	Prevalence and characterization of exercise oscillatory ventilation in apparently healthy individuals at variable risk for cardiovascular disease: A subanalysis of the EURO-EX trial. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 328-34	3.9	21
53	Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?. <i>Journal of Endocrinological Investigation</i> , 2016 , 39, 131-42	5.2	18
52	Non-Sexual Implications of Phosphodiesterase Type 5 Inhibitors. <i>Sexual Medicine Reviews</i> , 2017 , 5, 170-190	19.0	11
51	Phosphodiesterase 2 as a Therapeutic Target for Heart Failure: Is Upregulation an Option?. <i>Circulation Research</i> , 2017 , 120, 13-16	15.7	
50	New pharmacological approaches in heart failure therapy: developments and possibilities. <i>Future Cardiology</i> , 2017 , 13, 173-188	1.3	
49	Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials. <i>BMC Cardiovascular Disorders</i> , 2017 , 17, 150	2.3	23
48	Taurine supplementation has anti-atherogenic and anti-inflammatory effects before and after incremental exercise in heart failure. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2017 , 11, 185-194	3.4	26
47	Exertional Oscillatory Ventilation and Central Sleep Apnea in Heart Failure: Siblings, Cousins, or What Else?. 2017 , 183-202		1
46	Cardiopulmonary Exercise Testing: What Is its Value?. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1618-1636	15.1	157
45	Therapeutic benefits of phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis. <i>Interventional Medicine & Applied Science</i> , 2017 , 9, 123-135	0.7	2
44	Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases. <i>Annual Review of Pharmacology and Toxicology</i> , 2017 , 57, 455-479	17.9	61
43	Treatment of pulmonary hypertension with left heart disease: a concise review. <i>Vascular Health and Risk Management</i> , 2017 , 13, 415-420	4.4	5

42	Multiple Avenues of Modulating the Nitric Oxide Pathway in Heart Failure Clinical Trials. <i>Current Heart Failure Reports</i> , 2018 , 15, 44-52	2.8	9
41	MicroRNA-19a/b-3p protect the heart from hypertension-induced pathological cardiac hypertrophy through PDE5A. <i>Journal of Hypertension</i> , 2018 , 36, 1847-1857	1.9	21
40	Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2018 , 137, e578-e622	16.7	264
39	Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. <i>European Heart Journal</i> , 2018 , 39, 1255-1264	9.5	105
38	Macitentan in pulmonary hypertension due to left ventricular dysfunction. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	84
37	Pulmonary hypertension-targeted therapies in heart failure: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2018 , 13, e0204610	3.7	7
36	Pulmonary vasodilator therapies are of no benefit in pulmonary hypertension due to left heart disease: A meta-analysis. <i>International Journal of Cardiology</i> , 2018 , 273, 213-220	3.2	15
35	The Role of Gas Exchange Variables in Cardiopulmonary Exercise Testing for Risk Stratification and Management of Heart Failure with Reduced Ejection Fraction. <i>American Heart Journal</i> , 2018 , 202, 116-126	4.9	21
34	Pulmonary Hypertension and Heart Failure: A Dangerous Liaison. <i>Heart Failure Clinics</i> , 2018 , 14, 297-309	3.3	10
33	Efficacy and Safety of the Use of Pulmonary Arterial Hypertension Pharmacotherapy in Patients with Pulmonary Hypertension Secondary to Left Heart Disease: A Systematic Review. <i>Pharmacotherapy</i> , 2019 , 39, 929-945	5.8	4
32	Pulmonary Hypertension. 2019 , 327-341.e9		
31	Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894020948780	2.7	2
30	Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 977-992	3.8	12
29	Therapeutic options for chronic kidney disease-associated pulmonary hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2020 , 29, 497-507	3.5	1
28	PDE5 Inhibitors in Type 2 Diabetes Cardiovascular Complications. <i>Endocrines</i> , 2020 , 1, 90-101	0.8	2
27	Pulmonary Hypertension Due to Left Heart Disease: Diagnosis, Pathophysiology, and Therapy. <i>Hypertension</i> , 2020 , 75, 1397-1408	8.5	21
26	Muscarinic-dependent phosphorylation of the cardiac ryanodine receptor by protein kinase G is mediated by PI3K-AKT-nNOS signaling. <i>Journal of Biological Chemistry</i> , 2020 , 295, 11720-11728	5.4	2
25	Pulmonary Hypertension Due to Left Heart Disease-A Practical Approach to Diagnosis and Management. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 572-584	3.8	4

24	Effectiveness of Sildenafil in Pulmonary Hypertension Secondary to Valvular Heart Disease: A Systematic Review and Meta-Analysis. <i>Archives of Pharmacy Practice</i> , 2021 , 12, 55-65	0	0
23	Pulmonary vasodilator use in continuous-flow left ventricular assist device management. <i>Annals of Translational Medicine</i> , 2021 , 9, 522	3.2	
22	Cyclic guanosine monophosphate and 10-year change in left ventricular mass: the Multi-Ethnic Study of Atherosclerosis (MESA). <i>Biomarkers</i> , 2021 , 26, 309-317	2.6	0
21	Clinical and hemodynamic effects of oral sildenafil on biventricular function on patients with left ventricular systolic dysfunction. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14171	2.9	0
20	Pulmonary Hypertension in Left Heart Disease. <i>Clinics in Chest Medicine</i> , 2021 , 42, 39-58	5.3	5
19	Impact of targeted pulmonary arterial hypertension therapy in patients with combined post- and precapillary pulmonary hypertension. <i>American Heart Journal</i> , 2021 , 235, 74-81	4.9	2
18	Therapeutic Challenges and Emerging Treatment Targets for Pulmonary Hypertension in Left Heart Disease. <i>Journal of the American Heart Association</i> , 2021 , 10, e020633	6	4
17	Management of Pulmonary Hypertension in Left Heart Disease. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021 , 17, 115-123	2.1	2
16	Current Status of Pharmacologic and Nonpharmacologic Therapy in Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2021 , 17, 463-482	3.3	0
15	Current trends and future perspectives for heart failure treatment leveraging cGMP modifiers and the practical effector PKG. <i>Journal of Cardiology</i> , 2021 , 78, 261-268	3	3
14	Pre-Operative Sildenafil for Patients With Pulmonary Hypertension Undergoing Mitral Valve Surgery: A Systematic Review and Meta-Analysis. <i>Cardiology Research</i> , 2019 , 10, 369-377	1.8	6
13	Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis. <i>Journal of Clinical Medicine Research</i> , 2017 , 9, 488-498	2.9	21
12	Pulmonary Hypertension in Patients Without Pulmonary Arterial Hypertension. 2016 , 29-61		
11	Novel treatments for diastolic heart failure. 2020 , 95-127		
10	Sildenafil as an Eligible Heart Transplantation Therapy for Advanced Heart Failure Associated with Fixed Pulmonary Hypertension. <i>Arquivos Brasileiros De Cardiologia</i> , 2021 , 116, 227-228	1.2	
9	Reactive Oxygen Species Induced Pathways in Heart Failure Pathogenesis and Potential Therapeutic Strategies.. <i>Biomedicines</i> , 2022 , 10,	4.8	3
8	Analysis of Reasonable Respiratory Efficiency in Tennis Competition and Training Environment Based on Cloud Computing.. <i>Journal of Healthcare Engineering</i> , 2022 , 2022, 4289667	3.7	
7	Excess ventilation and exertional dyspnoea in heart failure and pulmonary hypertension. <i>European Respiratory Journal</i> , 2200144	13.6	2

6	Effects of Eb blocker therapy on exercise oscillatory ventilation in reduced ejection fraction heart failure patients: A case series study. <i>Biomedicine and Pharmacotherapy</i> , 2022 , 152, 113106	7.5	o
5	Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial. <i>Science Translational Medicine</i> , 2022 , 14,	17.5	1
4	Moving beyond the Vasodilator Model in Heart Failure with reduced Ejection Fraction - Lessons from Sildenafil. <i>European Journal of Heart Failure</i> ,	12.3	
3	Investigation of Genes and Proteins Expression Associating Serotonin Signaling Pathway in Lung and Pulmonary Artery Tissues of Dogs with Pulmonary Hypertension Secondary to Degenerative Mitral Valve Disease: The Preliminary Study. 2022 , 9, 530		o
2	Exertional oscillatory ventilation in subjects without heart failure reporting chronic dyspnoea. 00324-2022		o
1	Determinants of prognosis and management of patients with pulmonary hypertension due to left heart disease: a systematic review. 2023 , 28, 5115		o